CLINICAL TRIALS PROFILE FOR TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
✉ Email this page to a colleague
All Clinical Trials for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01378299 ↗ | CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy | Completed | Baylor College of Medicine | Phase 1 | 2011-10-01 | Testosterone (T) replacement prevents bone loss and relieves symptoms associated with androgen deficiency in male patients with hypogonadism, but at the expense of an increase in prostate-related adverse events and in the hematocrit values above the normal which may lead to bad circulatory outcomes. Most of the effects of T on the male skeleton are mediated by its conversion to estradiol (E2) by the enzyme aromatase. Genetic variations in the aromatase (CYP19A1) gene result in enzymes with variable activity and variable levels of E2 and T. This project is designed to determine if genetic variations in the CYP19A1 gene will result in differences in the skeletal response and incidence of side effects from T treatment in patients with low T. A large number of male Veterans are on T. Results from this project will help identify patients who would benefit from the therapy from those at risk for side effects, and would definitely have an impact in the future care of these patients and male patients in general once genetic profiling becomes part of the standard of care. |
| NCT01378299 ↗ | CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy | Completed | VA Office of Research and Development | Phase 1 | 2011-10-01 | Testosterone (T) replacement prevents bone loss and relieves symptoms associated with androgen deficiency in male patients with hypogonadism, but at the expense of an increase in prostate-related adverse events and in the hematocrit values above the normal which may lead to bad circulatory outcomes. Most of the effects of T on the male skeleton are mediated by its conversion to estradiol (E2) by the enzyme aromatase. Genetic variations in the aromatase (CYP19A1) gene result in enzymes with variable activity and variable levels of E2 and T. This project is designed to determine if genetic variations in the CYP19A1 gene will result in differences in the skeletal response and incidence of side effects from T treatment in patients with low T. A large number of male Veterans are on T. Results from this project will help identify patients who would benefit from the therapy from those at risk for side effects, and would definitely have an impact in the future care of these patients and male patients in general once genetic profiling becomes part of the standard of care. |
| NCT01750398 ↗ | Bipolar Androgen-based Therapy for Prostate Cancer (BAT) | Completed | Sidney Kimmel Comprehensive Cancer Center | Phase 2 | 2013-01-01 | The purpose of this study is to determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the effect of alternating therapy on quality of life and metabolic changes associated with androgen-deprivation therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Condition Name
Clinical Trial Locations for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Trials by Country
Clinical Trial Progress for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Clinical Trial Phase
Clinical Trial Sponsors for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Sponsor Name
